Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders

The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented. HU controls thrombocytosis both in polycythemia vera (PV) and in essential thrombocythemia (ET), while reducing the risk of thrombosis.1 Despite many anectodal reports, no evaluation of the prevalence and type of si...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) 2005-02, Vol.90 (2), p.261-262
Main Authors: Randi, ML, Ruzzon, E, Luzzatto, G, Tezza, F, Girolami, A, Fabris, F
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Busulfan - pharmacology
Enzyme Inhibitors - pharmacology
Female
Hematologic and hematopoietic diseases
Humans
Hydroxyurea - adverse effects
Hydroxyurea - pharmacology
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - genetics
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - metabolism
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Middle Aged
Myeloproliferative Disorders - drug therapy
Platelet diseases and coagulopathies
Polycythemia Vera - drug therapy
Retrospective Studies
Thrombocytosis - drug therapy
Time Factors
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented. HU controls thrombocytosis both in polycythemia vera (PV) and in essential thrombocythemia (ET), while reducing the risk of thrombosis.1 Despite many anectodal reports, no evaluation of the prevalence and type of side effects of HU exists in large series of patients.
ISSN:0390-6078
1592-8721